{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T17:10:12Z","timestamp":1771002612022,"version":"3.50.1"},"reference-count":46,"publisher":"Oncology Nursing Society (ONS)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Journal of Oncology Nursing"],"published-print":{"date-parts":[[2012,2,1]]},"DOI":"10.1188\/12.cjon.56-64","type":"journal-article","created":{"date-parts":[[2012,2,2]],"date-time":"2012-02-02T22:55:45Z","timestamp":1328223345000},"page":"56-64","source":"Crossref","is-referenced-by-count":10,"title":["Update on the Management of Neuroendocrine Tumors: Focus on Somatostatin Antitumor Effects"],"prefix":"10.1188","volume":"16","author":[{"given":"Nancy M.","family":"Gardner-Roehnelt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2012,2,1]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1185\/03007990903328959","article-title":"From somatostatin to octreotide LAR: Evolution of a somatostatin analogue","volume":"25","author":"L. Anthony","year":"2009","journal-title":"Current Medical Research and Opinion"},{"key":"2","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.bpg.2005.03.006","article-title":"Endocrine tumours of the gastrointestinal tract. Introduction: definition, historical aspects, classification, staging, prognosis, and therapeutic options","volume":"19","author":"R. Arnold","year":"2005","journal-title":"Best Practice and Research: Clinical Gastroenterology"},{"key":"3","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/0026-0495(92)90044-B","article-title":"Gastroenteropancreatic endocrine tumors: Effect of Sandostatin on tumor growth. The German Sandostatin Study Group","volume":"41","author":"R. Arnold","year":"1992","journal-title":"Metabolism"},{"key":"4","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/BF01655111","article-title":"Somatostatin analog sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors","volume":"17","author":"R. Arnold","year":"1993","journal-title":"World Journal of Surgery"},{"key":"5","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S1542-3565(05)00481-7","article-title":"Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: A randomized trial","volume":"3","author":"R. Arnold","year":"2005","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"6","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1136\/gut.38.3.430","article-title":"Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours","volume":"38","author":"R. Arnold","year":"1996","journal-title":"Gut"},{"key":"7","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1177\/0091270005277936","article-title":"Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles","volume":"45","author":"B. Astruc","year":"2005","journal-title":"Journal of Clinical Pharmacology"},{"key":"8","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1097\/MPA.0b013e3181ebb2a5","article-title":"The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: Well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum","volume":"39","author":"J. Boudreaux","year":"2010","journal-title":"Pancreas"},{"key":"9","volume-title":"WHO classification of tumours of the digestive system","author":"F. Bosman","year":"2010"},{"key":"10","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1586\/17446651.2.2.129","article-title":"Octreotide for acromegaly","volume":"2","author":"R. Cozzi","year":"2007","journal-title":"Expert Reviews of Endocrinology and Metabolism"},{"key":"11","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1677\/erc.0.0100451","article-title":"Somatostatin receptors in gastroenteropancreatic neuroendocrine tumours","volume":"10","author":"W. de Herder","year":"2003","journal-title":"Endocrine-Related Cancer"},{"key":"12","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1002\/(SICI)1097-0142(19960115)77:2<402::AID-CNCR25>3.0.CO;2-4","article-title":"Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group","volume":"77","author":"M. di Bartolomeo","year":"1996","journal-title":"Cancer"},{"key":"13","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1111\/j.1572-0241.2000.03210.x","article-title":"The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors","volume":"95","author":"M. Ducreux","year":"2000","journal-title":"American Journal of Gastroenterology"},{"key":"14","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1200\/JCO.2003.12.142","article-title":"Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors\u2014The International Lanreotide and Interferon Alfa Study Group","volume":"21","author":"S. Faiss","year":"2003","journal-title":"Journal of Clinical Oncology"},{"key":"15","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1677\/ERC-07-0288","article-title":"Somatostatin analogues in the control of neuroendocrine tumours: Efficacy and mechanisms","volume":"15","author":"S. Grozinsky-Glasberg","year":"2008","journal-title":"Endocrine-Related Cancer"},{"key":"16","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1210\/er.2000-0001","article-title":"The pathophysiological consequences of somatostatin receptor internalization and resistance","volume":"24","author":"L. Hofland","year":"2003","journal-title":"Endocrine Reviews"},{"key":"17","unstructured":"Ipsen Pharma Biotech. (2011). <i>Somatuline\u00ae depot (lanreotide injection)<\/i> [Package insert]. Signes, France: Author."},{"key":"18","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3109\/0284186X.2010.492791","article-title":"Nordic guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours","volume":"49","author":"E. Janson","year":"2010","journal-title":"Acta Oncologica"},{"key":"19","article-title":"Effective inhibition of human neuroendocrine tumor cell proliferation by a TOR kinase inhibitor and a novel somatostatin receptor agonist, pasireotide","author":"M. Kidd","year":"2010"},{"key":"20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3747\/co.v17i3.484","article-title":"Consensus recommendations for the diagnosis and management of well-differentiated gastroenterohepatic neuroendocrine tumours","volume":"17","author":"W. Kocha","year":"2010","journal-title":"Current Oncology"},{"key":"21","first-page":"933","article-title":"Antitumor effect of a neutralizing antibody to vascular endothelial growth factor on liver metastasis of endocrine neoplasm. Japanese","volume":"89","author":"H. Konno","year":"1998","journal-title":"Journal of Cancer Research"},{"key":"22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/01.cco.0000198018.53606.62","article-title":"Treatment of advanced carcinoid tumors","volume":"18","author":"A. Lai","year":"2006","journal-title":"Current Opinion in Oncology"},{"key":"23","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1210\/jc.2008-1919","article-title":"Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro","volume":"94","author":"S. Lesche","year":"2009","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"24","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1517\/14656566.9.15.2617","article-title":"Pharmacotherapy of neuroendocrine cancers","volume":"9","author":"I. Modlin","year":"2008","journal-title":"Expert Opinion in Pharmacotherapy"},{"key":"25","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/cncr.11105","article-title":"A 5-decade analysis of 13,715 carcinoid tumors","volume":"97","author":"I. Modlin","year":"2003","journal-title":"Cancer"},{"key":"26","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1172\/JCI19933","article-title":"Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis","volume":"114","author":"R. Murray","year":"2004","journal-title":"Journal of Clinical Investigation"},{"key":"27","unstructured":"National Comprehensive Cancer Network. (2011). <i>NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine tumors<\/i> [v.3.2011]. Retrieved from <a target=\"_blank\" href='http:\/\/www.nccn.org\/professionals\/drug_compendium\/content\/PDF\/60_4_4_2011.pdf'>http:\/\/www.nccn.org\/professionals\/drug_compendium\/content\/PDF\/60_4_4_2011.pdf<\/a>"},{"key":"28","unstructured":"Novartis Pharmaceuticals. (2010a). <i>Sandostatin\u00ae injection (octreotide acetate for injectable suspension)<\/i> [Package insert]. East Hanover, NJ: Author."},{"key":"29","unstructured":"Novartis Pharmaceuticals. (2010b). <i>Sandostatin\u00ae LAR depot (octreotide acetate for injectable suspension)<\/i> [Package insert]. East Hanover, NJ: Author."},{"key":"30","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1200\/JCO.2009.23.6711","article-title":"Is it time to widen the use of somatostatin analogs in neuroendocrine tumors?","volume":"27","author":"K. Oberg","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"31","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2)","volume":"10","author":"M. Pavel","year":"2011","journal-title":"Lancet"},{"key":"32","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/MPA.0b013e3181ec1380","article-title":"NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: Well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus)","volume":"39","author":"A. Phan","year":"2010","journal-title":"Pancreas"},{"key":"33","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"E. Raymond","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"34","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/0306-4522(95)00072-Q","article-title":"Molecular properties of somatostatin receptors","volume":"67","author":"T. Reisine","year":"1995","journal-title":"Neuroscience"},{"key":"35","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/ijc.2910560513","article-title":"High density of somatostatin receptors in veins surrounding human cancer tissue: Role in tumor-host interaction?","volume":"56","author":"J. Reubi","year":"1994","journal-title":"International Journal of Cancer"},{"key":"36","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1023\/A:1008383132024","article-title":"Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide","volume":"11","author":"S. Ricci","year":"2000","journal-title":"Annals of Oncology"},{"key":"37","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/00000421-200008000-00020","article-title":"Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors","volume":"23","author":"S. Ricci","year":"2000","journal-title":"American Journal of Clinical Oncology"},{"key":"38","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group","volume":"27","author":"A. Rinke","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"39","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.mce.2007.09.006","article-title":"Pasireotide (SOM23): Development, mechanism of action, and potential applications","volume":"286","author":"H. Schmid","year":"2008","journal-title":"Molecular and Cellular Endocrinology"},{"key":"40","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/cncr.10195","article-title":"Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma","volume":"94","author":"H. Shojamanesh","year":"2000","journal-title":"Cancer"},{"key":"41","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/annonc\/mdl105","article-title":"Rationale for the use of somatostatin analogs as antitumor agents","volume":"17","author":"C. Susini","year":"2006","journal-title":"Annals of Oncology"},{"key":"42","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1210\/en.2005-1479","article-title":"Role of complex cyclin d1\/cdk4 in somatostatin subtype 2 receptor-mediated inhibition of cell proliferation of a medullary thyroid carcinoma cell line in vitro","volume":"147","author":"F. Tagliati","year":"2006","journal-title":"Endocrinology"},{"key":"43","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"346","author":"J. Yao","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"44","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \"carcinoid:\" Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"J. Yao","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"45","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1200\/JCO.2009.24.2669","article-title":"Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: A phase II trial","volume":"28","author":"J. Yao","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"46","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1200\/JCO.2008.16.7858","article-title":"Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: Results of a phase II study","volume":"26","author":"J. Yao","year":"2008","journal-title":"Journal of Clinical Oncology"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/ons.metapress.com\/index\/W701U3440WV34Q75.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:48:09Z","timestamp":1763754489000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/16\/1\/update-management-neuroendocrine-tumors-focus-somatostatin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,2,1]]}},"alternative-id":["W701U3440WV34Q75"],"URL":"https:\/\/doi.org\/10.1188\/12.cjon.56-64","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"value":"1092-1095","type":"print"},{"value":"1538-067X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,1]]}}}